Evolus

We are excited to share that Evolus will be attending The Aesthetic MEET in Austin, TX this week! Stop by booth #1406 to meet our team, experience the latest in aesthetic #innovation, and learn how we are empowering practices with our unique cash-pay focus. Looking forward to connecting with industry leaders, practitioners, and friends. See you there! $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Last week, our CEO David Moatazedi, CFO Sandra Beaver, and CMO Rui Avelar, MD represented Evolus at the #Leerink Global Healthcare Conference and #Barclays Healthcare Conference. They shared insights on the strong momentum of our flagship #neurotoxin, the anticipated launch of our Evolysse™ injectable HA gel line, and our vision for 2025 and beyond. Catch the replay of these discussions here: https://lnkd.in/eWyZ-uJJ $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

We’re excited to share we’ve chosen Milan as the home of our Evolus International HQ!    Milan is the perfect fit for Evolus as a #performancebeauty company. It’s a vibrant business and cultural hub with a thriving ecosystem in design and beauty. Milan offers access to top talent and has great connections to Europe and beyond. These qualities align perfectly with who we are and how we operate.    The decision to establish an Evolus International HQ reflects our rapid growth, our commitment to global expansion and our belief that we are building something truly special. Our new HQ will reflect our cultural values, fostering collaboration and a shared sense of purpose to elevate performance beauty on the world stage.    We want our customers to experience our values firsthand. Our success is built on clinical and medical education. That’s why our International HQ will feature facilities allowing for cutting-edge scientific exchange and hands-on collaboration between employees and customers.    Stay tuned as we create a world-class hub that reflects our culture of grit, impact, fun and transparency!   Ciao Milano. Evolve with us.   #PerformanceBeautyInternational #EvolveWithUs #MilanHQ #GlobalEvolution

Earlier this week, we announced our Q4 and full-year 2024 results, achieving profitability ahead of expectations and delivering our fifth consecutive year of revenue growth exceeding 30% as we continued to gain market share with our neurotoxin. With the upcoming launch of Evolysse™ in 2025, we are expanding our #performancebeauty portfolio with a differentiated technology and creating new opportunities for long-term growth. The combination of Jeuveau® and Evolysse™ brings together the fastest growing neurotoxin in the U.S. with the first #innovation in HA technology in a decade. As we look ahead, we remain focused on driving strong financial performance and executing our strategy to reach at least $700M in revenue by 2028.

Today, we reported our Q4 and full year 2024 financials, marking our fourth year as the fastest growing toxin.    Our management team will hold a conference call to discuss the results today at 4:30 p.m. ET.    Read the release and access the conference call link here: https://lnkd.in/eRxQeg5P   $EOLS #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

The Evolus management team will be in Miami for two major investor conferences, where they will participate in fireside chats and investor meetings, sharing insights on our #performance beauty strategy and growth plans.   • The Leerink Partners Global Biopharma Conference, the fireside chat will take place on Tuesday, March 11, 2025, at 9:20 AM ET.    • The Barclays 27th Annual Global Healthcare Conference, the fireside chat will take place on Wednesday, March 12, 2025, at 3:30 PM ET.     Join us for the fireside chats on our Investor Relations page here: https://lnkd.in/eWyZ-uJJ     #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

The Evolus management team is excited to participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on February 27. As part of the event, our President and CEO David Moatazedi, will host a fireside chat from 9:30am – 10:00am ET to discuss our leadership in #performance beauty and the continued growth of Evolus. Tune in to the live webcast or catch the replay on our Investor Relations page here: https://lnkd.in/eWyZ-uJJ #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics

Evolus has achieved a major milestone with FDA approval of Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, marking our entry into the U.S. HA dermal filler market. This technological breakthrough expands our addressable market by 78% and accelerates our transformation into a multi-product leader in #performance beauty.   Evolysse™ introduces the first major #innovation in injectable HA dermal fillers in a decade, powered by SYMATESE’s Cold-X™ technology for long-lasting, natural-looking results. Launching in Q2 2025, these products will seamlessly integrate with our fast-growing neurotoxin business, leveraging our strong customer relationships, innovative co-branded marketing, and competitive brand positioning.   With a high overlap between the customer and consumer base for neurotoxins and fillers, Evolysse™ is perfectly positioned to drive significant value. Supported by one of the most extensive clinical trial programs in HA filler history, Evolysse™ products are being evaluated for safety and effectiveness in over 2,000 patients globally. This is just the beginning – we look forward to expanding the Evolysse™ collection with Evolysse™ Sculpt in 2026 and Evolysse™ Lips in 2027! Read the full press release: https://lnkd.in/eJctksm8   #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics 

IMCAS 2025 was even bigger and busier than ever before. More than 20,000 attendees from around the world converged on Paris last weekend demonstrating the interest and growth in this buoyant sector.    Evolus CEO David Moatazedi participated in a dynamic panel discussion at the IMCAS Tribune, focusing on neurotoxins and the future of the aesthetics industry. He shared insights on evolving consumer expectations and why the future lies in enhancing the #performance beauty experience, including a deep dive into Evolus’ innovative products, such as Evolysse™ and Estyme™.   David was joined in Paris by Dr. Rui Avelar, MD, our CMO and Head of R&D, who presented a paper on the next generation of injectable hyaluronic acid gels. Evolysse™ represents the first major technological breakthrough in HA dermal fillers in a decade, raising the standard for performance. These injectable HA gels are currently in the late stages of the U.S. regulatory approval process, with plans, upon approval, for a launch starting in Q2 2025.   #Evolus #IMCAS2025 #PerformanceBeauty #MedicalAesthetics

Evolus CEO David Moatazedi recently joined Oliver Renick on the Schwab Network to discuss our continued growth and the exciting road ahead. We have captured 13% market share with Jeuveau®, the fastest-growing neurotoxin in the U.S. for four consecutive years and are preparing to expand our portfolio with the upcoming launch of Evolysse™, our line of unique injectable hyaluronic acid (HA) gels.   Evolysse™ represents the first breakthrough technological #innovation in the HA filler market in over a decade and is being evaluated in over 2,000 patients globally. With FDA approval expected in the next 90 days and a planned launch in Q2 2025, we are excited to bring this highly differentiated Cold-X™ technology to the cash-pay aesthetics market, strengthening our leadership in #performance beauty.   As a company that has delivered over 30% revenue growth for five years, we are well-positioned to build on this momentum. With a strong foundation in place and a growing portfolio, we look forward to continuing to redefine aesthetics and drive long-term value for our customers and shareholders. https://lnkd.in/eZeqaSQM   $EOLS #Evolus #EvolveWithUs #PerformanceBeauty #MedicalAesthetics